Takeda Pharma Files 6-K Report

TL;DR

Takeda filed a routine 6-K, no new info, just confirming 20-F filings.

AI Summary

Takeda Pharmaceutical Company Limited filed a Form 6-K on September 25, 2025, reporting its status as a foreign private issuer. The filing indicates that Takeda will file its annual reports under Form 20-F. No specific financial or operational details beyond the filing type and date were provided in this document.

Why It Matters

This filing confirms Takeda's reporting status with the SEC, which is a standard procedural requirement for foreign private issuers. It does not contain new operational or financial information.

Risk Assessment

Risk Level: low — This is a routine administrative filing by Takeda, providing no new material information that would impact its risk profile.

Key Players & Entities

• Takeda Pharmaceutical Company Limited (company) — Filer of the report
• 0001395064-25-000143 (accession_number) — Accession number for the filing
• 20250925 (date) — Filing date and period of report
• 001-38757 (sec_file_number) — SEC file number for Takeda

FAQ

Filing Documents

• form6k_092525.htm (6-K) — 33KB
• 0001395064-25-000143.txt ( ) — 34KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date September 25, 2025 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller News Release Information About General Reserve and Other Voluntary Reserves OSAKA, Japan and CAMBRIDGE, Massachusetts, September 25, 2025 – Takeda ( TSE4502NYSETAK ) announces that its Board of Directors approved, on September 24, 2025 (U.S. Eastern Time), a reversal of general reserve and unrestricted reversal of other voluntary reserves, as detailed below. Takeda has established a provision in its Articles of Incorporation to the effect that the matters specified in each item of Paragraph 1, Article 459 of the Companies Act of Japan may be conducted by resolution of the Board of Directors. This treatment within the net assets section on Takeda Pharmaceutical Company Limited's balance sheet (unconsolidated) does not affect the consolidated financial results. 1. Details Reversal of voluntary reserves listed below including the general reserve, and reclassification of those reserves to unappropriated retained earnings. (1) Surplus items to be decreased, and their amounts (JPY) Reserve for retirement benefits 5,000 million Reserve for dividends 11,000 million Reserve for research and development 2,400 million Reserve for capital improvements 1,054 million Reserve for promotion of exports 434 million General reserve 814,500 million (2) Surplus item to be increased, and the amount (JPY) Unappropriated retained earnings 834,388 million 2. Reason for reversal of the general reserve and other voluntary reserves To enable a flexible capital policy by effectively utilizing a portion of the internal reserves that were accumulated in the past and remained unused over many years. 3. Effective date Septe

Forward-Looking Statements

Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could", "anticipates", "estimates", "projects", "forecasts", "outlook" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations competitive pressures and developments changes to applicable laws and regulations, including tax, tariff and other trade-related rules challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof uncertainty of commercial success for new and existing products manufacturing difficulties or delays fluctuations in interest and currency exchange rates claims or concerns regarding the safety or efficacy of marketed products or product candidates the impact of health crises, like the novel coronavirus pandemic the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or o

View Full Filing

View this 6-K filing on SEC EDGAR